University of Arkansas
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Arkansas sits in the top decile of US sponsors by registered trial count (#113 of 15,742 sponsors by registered trial count).
University of Arkansas: 318 sponsored US clinical trials, 37 recruiting.
University of Arkansas sponsors 318 registered US clinical trials on ClinicalTrials.gov, 37 of them currently recruiting, and 202 completed. 17 of these trials are in Phase 3-4 (later-stage) and 102 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 15 trials.
Top-decile sponsor footprint
University of Arkansas ranks in the top decile of sponsors by registered trial count (#113 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
202 of 262 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
318 total, page 5 of 7
Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients With Colon Cancer
NCT01479894
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
NCT01177735
Telemedicine Versus Traditional Treatment of Muscle Tension Dysphonia
NCT01419444
Nutrient Synergy in Beef and Stimulation of Protein Synthesis in Elderly
NCT01415973
Vaccination of High Risk Breast Cancer Patients
NCT01390064
Doxazosin for Psychostimulant Dependence
NCT01371851
Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors
NCT01431872
Effects of Massage Therapy to Induce Sleep in Preterm Infants
NCT01354028
A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer
NCT01321697
Bone Microarchitecture at the Radius: a Pilot Comparison Between Children With Cystic Fibrosis and Healthy Controls
NCT01331980
UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
NCT01313897
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
NCT01240304
Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers
NCT01415986
Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals
NCT01262092
Carvedilol for Psychostimulant Dependence
NCT01171183
Effects of Amino Acids on Regional Lipid Metabolism
NCT01150188
Assessment of Bone Density and Bone Turnover Markers in Patients With Down Syndrome and Comparison to the Ts65Dn Model
NCT01148121
Cognitive Enhancement and Relapse Prevention in Cocaine Addiction
NCT01067846
Comparison of Virtual Reality and Passive Distraction on Burn Wound Care Pain in Adolescents
NCT01812655
The Use of Psychomotor Vigilance Testing in the Assessment of Pediatric Obstructive Sleep Apnea
NCT01276860
Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis
NCT01105715
UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
NCT01621672
Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia
NCT01085903
Drug Discrimination in Methadone-Maintained Humans Study 3
NCT01068847
Relationship of Preoperative Parathyroid Hormone (PTH) and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy
NCT01539486
Complications of Endocrine Surgery: Data From the United HealthSystem Consortium
NCT01539499
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
NCT01062230
Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin
NCT01178138
The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
NCT01010256
Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling
NCT01156454
Changing Thought and Action in Tobacco Dependence With Transcranial Magnetic Stimulation
NCT00973622
Studying Amphetamine Withdrawal in Humans
NCT01215929
Biotin Status in Pregnancy
NCT00894920
Lubiprostone as a Treatment for Constipation in Parkinson's Disease
NCT00669461
Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
NCT01018927
Effects of PS-IPC Supplementation on Muscle Mass and Functional Outcomes in Older Adults
NCT00926250
Panobinostat/Velcade in Multiple Myeloma
NCT00891033
Modafinil for Methamphetamine Dependence
NCT00859573
Keratometric Tear Breakup Time and Fluorescein Tear Breakup Time
NCT00854906
A Preliminary Study Utilizing a Flexible Endoscope for Pelvic Culdoscopy
NCT00848575
Effect of rTMS on Resting State Brain Activity in Tinnitus
NCT00926237
Personalized Interactive Laser Therapy of Port Wine Stain
NCT00782483
Open-Label Disulfiram for Methamphetamine Dependence
NCT00731133
Drug Discrimination in Methadone-Maintained Humans Study 2
NCT00733239
Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis
NCT00706004
Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease
NCT01545622
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
NCT00657553
Effect of Tai Chi on Osteoarthritic Knee Pain in Elders With Mild Dementia
NCT01528566
Methamphetamine-Quetiapine Interactions in Humans
NCT00567866
Translating the Diabetes Prevention Program (DPP) Lifestyle Intervention to Rural African-American Communities (HEALTHY Ways)
NCT01472588
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 40 |
| Phase 2 | 62 |
| Phase 3 | 13 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the University of Arkansas pipeline
37 recruiting of 318 indexed (12% open); 202 completed (64%).
Phase mix: 17 late (III/IV) vs 102 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Arkansas: open-pipeline peers nationwide
Peers matched on 318 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
University of Arkansas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 318 trials (± recruiting share)
- Rush University Medical Center · 320 trials · 17% recruiting
- Jonsson Comprehensive Cancer Center · 321 trials · 19% recruiting
- Allergan · 314 trials · 0% recruiting
- Celgene · 308 trials · 4% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Jazz Pharmaceuticals · 12% recruiting · 128 trials
- Abbott Diabetes Care · 12% recruiting · 26 trials
- Medtronic Vascular · 12% recruiting · 26 trials
- Midwest Center for Metabolic and Cardiovascular Research · 12% recruiting · 26 trials
Related
What to do with this University of Arkansas page
318 registered trials is a research-attention snapshot, not an endorsement of University of Arkansas or any single study.
- 37 of University of Arkansas's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition University of Arkansas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Arkansas pipeline card: 318 registered trials from official public datasets.Report a data error.